Thajudeen Bijin, Issa Dany, Roy-Chaudhury Prabir
Division of Nephrology, Banner University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724, USA.
WG (Bill) Hefner VA Medical Center, 1601 Brenner Ave, Salisbury, NC 28144, USA.
Fac Rev. 2023 May 16;12:12. doi: 10.12703/r/12-12. eCollection 2023.
End-stage renal disease (ESRD) continues to be a disease process with a high rate of hospitalization and mortality. There has been little innovation in nephrology over the last few decades compared to revolutionary high-tech advancements in other areas like oncology and cardiovascular medicine. Kidney transplantation, the only available alternative to renal replacement therapy, is limited in its availability. It is essential to have advances in this field to improve the efficiency of currently available treatments and devise new therapies. The current description of renal replacement therapy is inappropriate as it only replaces the filtration function of the failed kidney without addressing its other vital metabolic, endocrinologic, and immunologic roles and portability. Hence, it is critical to have newer therapies focusing on total replacement and portability, not just clearance. This review will address the developments in hemodialysis therapy. Advances in hemodialysis therapy include hemodiafiltration, portable machines, wearable artificial kidneys, and bioartificial kidneys. Although promising, newer technologies in this direction are still far from clinical application. Several organizations and enterprises including the Kidney Health Initiative and Kidney X: The Kidney Innovation Accelerator, as well as The Advancing American Kidney Health Initiative, are working in tandem to develop new therapies that could customize the treatment of ESRD.
终末期肾病(ESRD)仍然是一种住院率和死亡率都很高的疾病进程。与肿瘤学和心血管医学等其他领域的革命性高科技进展相比,过去几十年肾脏病学领域的创新很少。肾移植作为肾脏替代治疗的唯一可用选择,其可及性有限。该领域取得进展对于提高现有治疗方法的效率并设计新疗法至关重要。目前对肾脏替代治疗的描述并不恰当,因为它仅替代了衰竭肾脏的滤过功能,而未涉及肾脏其他重要的代谢、内分泌和免疫作用以及便携性。因此,至关重要的是要有专注于完全替代和便携性而非仅仅是清除功能的更新疗法。本综述将探讨血液透析治疗的进展。血液透析治疗的进展包括血液透析滤过、便携式机器、可穿戴人工肾和生物人工肾。尽管前景广阔,但该方向的新技术仍远未应用于临床。包括肾脏健康倡议组织和肾脏X:肾脏创新加速器以及推进美国肾脏健康倡议在内的多个组织和企业正在携手合作,开发能够定制ESRD治疗的新疗法。